Background As knowledge of mechanisms that drive the development of cancer grows,
there has been corresponding growth in therapies specific to a mechanism. While these …

Simple Summary The analysis of tumor-associated genetic variants and biomarkers is
critical for therapy choice, as specific mutations allow for a personalized treatment. Because …

Background Next-generation sequencing is used in cancer research to identify somatic and
germline mutations, which can predict sensitivity or resistance to therapies, and may be a …

Introduction The identification of tumour mutational burden (TMB) as a biomarker of
response to programmed cell death protein 1 (PD-1) immunotherapy has necessitated the …

Timely and accurate identification of molecular alterations in solid tumors is essential for
proper management of patients with advanced cancers. This has created a need for rapid …

The lack of validated, distributed comprehensive genomic profiling assays for patients with
cancer inhibits access to precision oncology treatment. To address this, we describe elio …

We developed and clinically validated a hybrid capture next generation sequencing assay to
detect somatic alterations and microsatellite instability in solid tumors and hematologic …

Massively parallel sequencing, also referred to as “next-generation sequencing”(NGS)
provides not only information about simple, single nucleotide alterations, but it can also …

Background Improvements in both performance and cost for next-generation sequencing
(NGS) have spurred its rapid adoption for clinical applications. We designed and optimized …

Introduction Next-generation sequencing (NGS) enables simultaneous detection of
actionable somatic variants and estimation of genomic signatures such as tumor mutational …